116 related articles for article (PubMed ID: 1708104)
1. Detoxification of pertussis toxin by site-directed mutagenesis: a review of connaught strategy to develop a recombinant pertussis vaccine.
Loosmore S; Cockle S; Zealey G; Boux H; Phillips K; Fahim R; Klein M
Mol Immunol; 1991 Mar; 28(3):235-8. PubMed ID: 1708104
[No Abstract] [Full Text] [Related]
2. The advent of recombinant pertussis vaccines.
Burnette WN
Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
[No Abstract] [Full Text] [Related]
3. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
4. Towards third-generation whooping cough vaccines.
Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L
Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047
[TBL] [Abstract][Full Text] [Related]
5. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
[TBL] [Abstract][Full Text] [Related]
6. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
7. Expression of pertussis toxin in Bordetella bronchiseptica and Bordetella parapertussis carrying recombinant plasmids.
Lee CK; Roberts A; Perrin S
Infect Immun; 1989 May; 57(5):1413-8. PubMed ID: 2707851
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
Loosmore S; Zealey G; Cockle S; Boux H; Chong P; Yacoob R; Klein M
Infect Immun; 1993 Jun; 61(6):2316-24. PubMed ID: 8500874
[TBL] [Abstract][Full Text] [Related]
9. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
10. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
[TBL] [Abstract][Full Text] [Related]
11. Detoxification of pertussis toxin by site-directed mutagenesis.
Cockle S; Loosmore S; Radika K; Zealey G; Boux H; Phillips K; Klein M
Adv Exp Med Biol; 1989; 251():209-14. PubMed ID: 2481961
[No Abstract] [Full Text] [Related]
12. Developments toward a recombinant pertussis vaccine.
Burnette WN; Whiteley DW; Mar VL; Burns DL; Kaslow HR; Cieplak W; Keith JM; Bartley TD
Adv Exp Med Biol; 1989; 251():1-7. PubMed ID: 2692423
[No Abstract] [Full Text] [Related]
13. Mutants of pertussis toxin suitable for vaccine development.
Pizza M; Covacci A; Bartoloni A; Perugini M; Nencioni L; De Magistris MT; Villa L; Nucci D; Manetti R; Bugnoli M
Science; 1989 Oct; 246(4929):497-500. PubMed ID: 2683073
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.
Arciniega JL; Shahin RD; Burnette WN; Bartley TD; Whiteley DW; Mar VL; Burns DL
Infect Immun; 1991 Oct; 59(10):3407-10. PubMed ID: 1894354
[TBL] [Abstract][Full Text] [Related]
15. Rational design of vaccines.
Rappuoli R
Nat Med; 1997 Apr; 3(4):374-6. PubMed ID: 9095163
[No Abstract] [Full Text] [Related]
16. Paradoxes of pertussis toxin.
Wardlaw AC
Zentralbl Bakteriol; 1990 May; 273(1):1-4. PubMed ID: 2194485
[No Abstract] [Full Text] [Related]
17. A recombinant DNA approach to the pertussis vaccine.
Rappuoli R; Nicosia A; Bartoloni A; Aricò B; Perugini M
Ann Sclavo Collana Monogr; 1986; 3(1-2):183-9. PubMed ID: 2892506
[No Abstract] [Full Text] [Related]
18. Bacterial ADP-ribosylating toxins: form, function, and recombinant vaccine development.
Burnette WN
Behring Inst Mitt; 1997 Feb; (98):434-41. PubMed ID: 9382767
[TBL] [Abstract][Full Text] [Related]
19. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide.
Vogel FR; Leclerc C; Schutze MP; Jolivet M; Audibert F; Klein TW; Chedid L
Cell Immunol; 1987 Jun; 107(1):40-51. PubMed ID: 2438053
[TBL] [Abstract][Full Text] [Related]
20. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
